BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tu WJ, McCuaig RD, Melino M, Rawle DJ, Le TT, Yan K, Suhrbier A, Johnston RL, Koufariotis LT, Waddell N, Cross EM, Tsimbalyuk S, Bain A, Ahern E, Collinson N, Phipps S, Forwood JK, Seddiki N, Rao S. Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. Cell Discov 2021;7:37. [PMID: 34031383 DOI: 10.1038/s41421-021-00279-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Tu WJ, McCuaig RD, Melino M, Rawle DJ, Le TT, Yan K, Suhrbier A, Johnston RL, Koufariotis LT, Waddell N, Cross EM, Tsimbalyuk S, Bain A, Ahern E, Collinson N, Phipps S, Forwood JK, Seddiki N, Rao S. Author Correction: Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. Cell Discov 2021;7:58. [PMID: 34315866 DOI: 10.1038/s41421-021-00308-8] [Reference Citation Analysis]
2 Dunn J, McCuaig RD, Tan AHY, Tu WJ, Wu F, Wagstaff KM, Zafar A, Ali S, Diwakar H, Dahlstrom JE, Bean EG, Forwood JK, Tsimbalyuk S, Cross EM, Hardy K, Bain AL, Ahern E, Dolcetti R, Mazzieri R, Yip D, Eastgate M, Malik L, Milburn P, Jans DA, Rao S. Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers. Cancers (Basel) 2022;14:1596. [PMID: 35326747 DOI: 10.3390/cancers14061596] [Reference Citation Analysis]
3 González-Paz L, Hurtado-León ML, Lossada C, Fernández-Materán FV, Vera-Villalobos J, Loroño M, Paz JL, Jeffreys L, Alvarado YJ. Structural deformability induced in proteins of potential interest associated with COVID-19 by binding of homologues present in ivermectin: Comparative study based in elastic networks models. J Mol Liq 2021;340:117284. [PMID: 34421159 DOI: 10.1016/j.molliq.2021.117284] [Reference Citation Analysis]
4 Zhang X, Wang X, Wu T, Yin W, Yan J, Sun Y, Zhao D. Therapeutic potential of targeting LSD1/ KDM1A in cancers. Pharmacol Res 2021;:105958. [PMID: 34718134 DOI: 10.1016/j.phrs.2021.105958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]